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Summary
Melanoma is the most common lethal cutaneous neoplasm.
In order to harmonise treatment and follow-up of melan-
oma patients, guidelines for the management of melanoma
in Switzerland were inaugurated in 2001 and revised in
2006. A new classification and recent results in randomised
trials necessitated changes concerning staging and modific-
ations of the recommendations of therapy and follow-up.
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Introduction
Cutaneous melanoma not only has a high incidence, but
is also the most aggressive of the cutaneous neoplasms.
For these reasons, treatment guidelines have been prepared
under the aegis of the Swiss Cancer League (skin cancer
group) and published in 2001 with a revised version in
2006 [1], with the aim of providing a reasonably practical
guide for all physicians (general practitioners, dermatolo-
gists, surgeons, oncologists, and others) who encounter cu-
taneous melanoma in their daily work. The recommenda-
tions presented in these guidelines have been graded ac-
cording to the amount of scientific evidence supporting
them using the “Level of Evidence” classification deve-
loped by the Canadian Medical Association, 1998.
The purpose of these updated guidelines is to ensure the ad-
equate treatment of melanoma patients in Switzerland. At
present, patients with low risk melanoma tend to be over-
treated, whereas the follow-up procedures for patients with
high risk or metastasing melanoma are sometimes inad-
equate. These guidelines were introduced in April 1999 in
the Departments of Dermatology in Geneva and Lausanne/
Switzerland and Zurich/Switzerland, and have been in use
since that time. Our experience with the guidelines showed
them to provide a valuable, practical basis for treating cu-
taneous melanoma. Drawing on the combined expertise of
a multidisciplinary team, the guidelines reflect current in-
ternational standards [2] and the state of the art. Modifica-
tions of these guidelines in special clinical situations are at
the discretion of the individual practitioner.
There are several important differences between the Swiss
recommendation and other recommendations:
1. The ABCD-rule does not contain diameter because
today many melanomas have diameter of less than 5
mm.
2. Based on daily experience the quality of the sentinel
lymph node procedure (surgery and histological
evaluation of the node) is sometimes poor in
Switzerland. The guidelines therefore underline the
necessity of sending patients with intermediate risk to
specialised centers in order to assure reasonable
quality.
3. The best population for an adjuvant interferon therapy
are patients with micrometastases and/or ulceration.
Pegylated interferon-alpha 2b weekly injected is
preferred based on its favourable pharmacology.
4. Compared to standard therapy, new molecules such as
ipilimumab and vemurafenib are promising treatment
options. In order to improve our knowledge about the
optimal use, translational research is essential. This
can only be done in specialised centers, therefore we
recommend that these patients are referred to and
treated in melanoma centers.
5. PET/CT scans are covered by the Swiss health
insurances for melanoma follow up and should be
preferentially used in the early periods in high risk
situations.
Medical progress and new information necessitated an up-
date of these recommendations in 2011.
Clinical melanoma subtypes
Superficial spreading melanoma (SSM) is the most com-
mon subtype (70%) and is characterised by an initial flat
phase that shows changes in size, shape or colour. SSM
may occur in young adults but the mean age is in the 40s.
Large numbers of melanocytic naevi and more than a few
dysplastic naevi are strong risk factors. SSM is associated
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with and has been linked to intermittent exposure and sun-
burn especially in adolescence and childhood.
Nodular melanoma (NM) accounts for about 15% of
melanomas overall, except for the majority of thick melan-
omas. It presents as a symmetrical, raised, firm, often uni-
formly coloured and frequently non-pigmented nodule that
is rapidly enlarging and becoming more raised. Bleeding
and crusting are common. NM occurs more often in older
people, particularly men, and is more commonly seen on
the head and neck than elsewhere.
Lentigo maligna (LM) and lentigo maligna melanoma
(LMM, the invasive form of LM) account for 10–15% of
melanomas. It has an initial flat phase that may be pro-
longed. It presents as an evolving pigmented macule and
has to be differentiated from seborrheic keratoses, solar
lentigines and pigmented actinic keratoses. LM has been
linked epidemiologically to large cumulative doses of UV
light, has a strong predilection for the head and neck, and
is more common in outdoor workers, in older people and
in association with solar damage and non-melanoma skin
cancer.
Acral lentiginous melanoma (ALM) accounts for 1–3%
of melanomas and occurs on the acral skin of the palms and
soles. It presents with a flat phase with similar appearances
and changes to SSM. Importantly, melanomas that appear
relatively flat on the soles of the feet may have significant
depth histologically. Although the epidemiology is not as
well understood, this type of melanoma is at least equally
common in people with dark skin and may have no rela-
tionship with UV exposure.
Rare variants of melanoma
There are some rare variants of melanoma such as melan-
oma of the nail matrix (subungual melanoma), of the mu-
cosa (e.g., oral cavity, esophagus, rectum, vagina) amelan-
otic melanoma, desmoplastic melanoma which represent
together not more than 5% of all melanomas.
Diagnosis of melanoma
Examination for melanoma detection requires examination
of the whole skin surface under good lighting. Dermoscopy
is a non invasive technique using a hand-held magnifying
device combined with either the application of a liquid
between the transparent plate of the device and the skin,
or the use of cross-polarised light. This technique allows
the visualisation of diagnostic features of pigmented skin
lesions that are not seen with the naked eye and has been
shown to significantly improve diagnostic accuracy com-
pared to naked eye examination in the hands of an experi-
enced investigator (level of evidence III).
Suspicious lesions are characterised by Asymmetry, Border
irregularities, Color heterogeneity, Dynamics, (Dynamics
in colors, elevation or size) (“ABCD rule”) [2, 3]. Dynam-
ics is the most important criterium for the diagnosis of thick
melanomas including amelanotic melanoma. Today, many
primary melanomas have a diameter of less than 5 mm [4].
Diagnosis should be based on a full thickness excisional
biopsy with a small side margin. Processing by an experi-
enced pathology institute is mandatory.
Staging
Physical examination with special attention to other suspi-
cious pigmented lesions, tumour satellites, in-transit meta-
stases, regional lymph node and systemic metastases is
mandatory.
In low-risk melanomas (tumour thickness <1 mm) no other
investigations are necessary. In higher stages imaging is re-
commended in order to allow proper staging.
The most recent version of the AJCC classification has
made a few changes. Mitotic activity was included as a cri-
terion for thin primary tumours. In addition, the assump-
tion was made that even solitary tumour cells should result
in N1a disease. The clinical relevance of this suggestion is
under discussion.
The refined version of the pTNM [5] system (table 1) is the
classification system of choice.
Therapy
Primary excision of suspicious lesions
Diagnosis should be based on a full thickness excisional
biopsy. Suspicious melanocytic lesions should be excised
completely, with a narrow clinical margin (level of eviden-
ce IV). The diagnosis of melanoma is made histologically.
The histology report should follow the WHO classification
and include maximum thickness in millimeters (Breslow),
presence of ulceration and mitosis, presence and extent of
regression and clearance of the surgical margins [6].
The final operative removal of the primary tumor should
be carried out within 4 to 6 weeks following primary re-
section, leaving a safety margin of 1–2 cm, depending on
the thickness of the tumor (table 2). Special localisations,
e.g. in the face, may necessitate exceptions from standard
safety margins. In these locations, radiotherapy might be
considered as an alternative for lentigo maligna (melan-
oma) [7].
Sentinel lymph node biopsy
In the past decade, sentinel lymph node biopsy (SLNB)
has become standard for staging patients diagnosed with
cutaneous melanoma. The method’s accuracy and reliabil-
ity and the status of the sentinel lymph node (SLN) as the
single most important prognostic factor for recurrence and
survival for melanoma patients has been proven beyond
any reasonable doubt (level of evidence IV) [8]. Neverthe-
less, the impact of sentinel lymph node biopsy (SLNB) on
survival remains unclear. There is general agreement that
SLNB will help identify patients who might benefit from
further therapy, such as complete lymph node dissection
(CLND) and adjuvant interferon therapy [9, 10], even if
clinical trials aiming to determine the impact of these ad-
juvant measures are still ongoing. The recently published
proceedings of an expert panel clarify the indication of
SLNB as a staging tool [8]: SLNB should be discussed with
and offered to all patients with primary melanoma with
Breslow thickness equal to or greater than 1.0 mm and clin-
ically normal regional lymph nodes (determined by physic-
al examination and ultrasound).
According the current TNM classification (UICC Interna-
tional Union Against Cancer, Issue 7) micro metastases
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have to be distinguished from isolated tumour cells. Isol-
ated tumour cells are single tumour cells or small clusters
of cells, that are smaller than 0.2 mm and can be detected
by immunohistochemistry and are also visible in conven-
tional stainings. Isolated tumour cells do not have typical
features of metastases such as proliferation or stroma reac-
tions and do not penetrate and do not show vasculature.
The pathology report of the sentinel lymph node-biopsy
should clearly distinguish between isolated tumour cells
and tumour cell clusters. In the case of micrometastases it
is essential to indicate the maximal diameter of the lymph
node metastasis. In order to provide high quality of his-
topathological assessments the histological diagnosis of
melanoma should be confirmed by a referenced pathologist
for quality reassurance [11].
The pathological investigation of the sentinel lymph node
is difficult and should be performed in pathology institutes
with large amounts of experience.
Completion lymph node dissection
In the pre-sentinel era, melanoma patients were subject to
elective lymph node dissections (ELND), which, however,
did not produce a statistically significant survival benefit
[12]. Following the introduction of SLNB as standard of
care in the treatment regime of cutaneous melanoma, com-
plete lymph node dissection (CLND) was recommended
according to the Augsburg Consensus guidelines [13] to
all patients with a positive SLNB. Thus, roughly 80% of
all patients, who were sentinel-negative, were spared elect-
ive lymph node dissection. Whereas SLNB is a minimally
invasive procedure with limited morbidity, CLND, much
like ELND, is associated with considerable complication
rates and socioeconomic costs [14]. Several studies report
an increased disease-free survival (DFS) with no signific-
ant impact on overall survival, raising the question wheth-
er lymph node dissection is necessary in case of a positive
SLNB. In a recent study, CLND reduced subsequent re-
gional lymph node metastases and improved disease-free
survival, while overall survival remained unaffected [15].
67–90% of SLN-positive patients do not have further non-
SLNs that contain tumour deposits in the CLND specimens
[16]. As a consequence, the majority (80%) of SLN-pos-
itive patients undergo unnecessary surgery associated with
considerable morbidity. Therefore, several authors have
tried to identify patient, tumour and SLN characteristics
predicting further non-SLN positivity to safely avoid
CLND [16]. Although previous studies have failed to con-
sistently identify the same clinicopathological features as
indicators for additional non-SLN positivity upon CLND
or for DFS [17], SLN tumour load, nevertheless, was uni-
formly confirmed by all of these studies as prognosticator
for non-SLN positivity and recurrence. CLND has not yet
been proven to improve overall melanoma-specific surviv-
al. However, Cascinelli et al. [18] have shown that CLND
Table 1: The 2009 staging system for cutaneous melanoma according to the AJCC [5].
Classification Thickness (mm) Ulceration Status/Mitoses
T
Tis NA NA
T1 ≤1.00 a: Without ulceration and mitosis <1/mm2
b: With ulceration or mitoses ≥1/mm2
T2 1.01–2.00 a: Without ulceration
b: With ulceration
T3 2.01–4.00 a: Without ulceration
b: With ulceration
T4 >4.00 a: Without ulceration
b: With ulceration
N No. of Metastatic Nodes Nodal Metastatic Burden
N0 0 NA
N1 1 a: Micrometastasis*
b: Macrometastasis†
N2 2–3 a: Micrometastasis*
b: Macrometastasis†
c: In transit metastases/satellites without metastatic nodes
N3 4+ metastatic nodes, or matted nodes, or in transit
metastases/satellites with metastatic nodes
M Site Serum LDH
M0 No distant metastases NA
M1a Distant skin, subcutaneous, or nodal metastases Normal
M1b Lung metastases Normal
M1c All other visceral metastases Normal
Any distant metastasis Elevated
Abbreviations: NA, not applicable; LDH, lactate dehydrogenase.
*Micrometastases are diagnosed after sentinel lymph node biopsy.
†Macrometastases are defined as clinically detectable nodal metastases confirmed pathologically
Table 2: Excision safety margins for surgical treatment of primary melanoma (pT1–4N0M0).
Tumour thickness (Breslow) Excision safety margin, cm
Melanoma in situ (tumour thickness is not indicated) (plisN0M0) 0.5
<2 mm (pT1–2N0M0) 1
>2 mm (pT3–4N0M0) 2
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is necessary to achieve the best assessment of prognosis
of stage IB and II melanoma and to identify those patients
who, having only positive sentinel nodes and negative non-
sentinel nodes, have a good prognosis. There is consid-
erable debate as to how to stratify SLN tumour burden;
Satzger et al. [19] found that isolated immunohistochemic-
ally positive tumour cells are without prognostic signific-
ance and DFS of these patients did not differ from that of
SLN-negative patients, an observation that is supported in
a broader sense by Van Akkooi et al. [20]. In their study,
no patient with an SLN tumour load of <0.1 mm had addi-
tional non-SLN positivity upon CLND, and 5-year overall
survival was 100%.
On the basis of these data, they suggested that such patients
may be considered SLN-negative and should be spared
CLND. There is currently no consensus among eminent
guidelines [8, 9] whether or not CLND should be recom-
mended for all patients with positive SLNB. Therefore, we
do not recommend CLND complete lymph node dissec-
tion in patients that present only isolated tumour cells in
their sentinel node until the presence of this pathological
feature has shown clear prognostic implications. Discrep-
ancies exist in particular as far as the role of the SLN tu-
mour burden is concerned and on the value of ultrasound-
guided follow-up, a method that can detect early recur-
rences in the regional nodal basin and prompt a CLND
only in patients with such evidence. Based on these dif-
fering expert opinions, the benefits and shortcomings of
CLND should be discussed with each patient with a posit-
ive SLNB carefully, until the currently ongoing Multicen-
ter Selective Lymphadenectomy Trial II has clarified these
issues. Recurrences in the regional nodal basis, irrespective
of whether it was previously staged or not, mandate lymph
node dissection [21]. However, before undertaking addi-
tional aggressive local surgical treatments, a detailed sta-
ging investigation, one including imaging techniques such
as CT scan or PET (positron emission tomography), is ne-
cessary to exclude the presence of further metastases.
Adjuvant therapy
Many clinical trials have investigated the impact of ad-
juvant treatment modalities in high risk melanoma.
However, solid evidence can only be gleaned from pro-
spective randomised multicenter trials. Neither ELND, per-
fusion of the extremities, radiotherapy, nor chemotherapy
have been able to identify a significant increase in the
length of survival rate benefit to the melanoma patient col-
lective as a whole [2]. Adjuvant treatment with viscum
album (Iscador®) is not recommended, since it might ac-
celerate the disease course [22]. Therefore, there is no gen-
erally accepted adjuvant therapy to date for patients with
high-risk primary melanoma or completely resected lymph
node metastases (stage III). Adjuvant immunotherapy with
interferon-α leads to a significant prolongation of disease-
free survival in some, but not all randomised trials. Sever-
al large independent trials using intermediate dose (also
pegylated interferon) have demonstrated a positive effect
on disease free and distant metastases-free survival in pa-
tients with micro metastases (N1a) [10]. In this patient
population and patients with primary ulcerated melanomas
interferon can be recommended, if the individual patient
tolerates it well (level of evidence III). Adjuvant treatment
in patients with resected macroscopic involvement (N1b)
should only be applied in the context of clinical trials in
specialised centers.
Surgery of distant metastasis
The purpose of treatment in the metastatic situation is usu-
ally to achieve a palliation. Surgery is the most effective
means of providing this, if it is technically feasible, if risk
of morbidity and mortality is low and if the patient is likely
to live long enough to derive a benefit. A PET CT scan
should be performed before surgery to exclude further le-
sions. Good examples for palliative surgery are single loc-
alised lesions to the brain, bowel, liver and lung or spinal
cord. In some patients a long time survival after complete
resection has been described [23].
Radiotherapy
Radiotherapy plays an important role in the palliation of
many symptoms in melanoma patients especially for symp-
tomatic brain metastases or localised and painful bone
metastases, as well as nerve compression symptoms. A
short course of radiotherapy is normally preferred and good
palliation can be obtained in two thirds of the cases. The
overall response rate reported with different fractional
doses ranges from 9–92% with a median of 50% [24–26].
Radiotherapy still represents a reasonable palliation
whenever surgery is not applicable (table 3).
Systemic treatment of metastatic melanoma
Patients should be included in well-designed clinical trials
whenever possible after genetic analysis of c-kit, N-Ras
and B-RAF. Unfortunately clinical trials are not available
for all melanoma patients. In these cases and in B-RAF
and c-kit wildtype patients, systemic treatment with Ipilim-
umab or monochemotherapy should be considered. Dacar-
bacine (DTIC) is one of the most used substances in meta-
static melanoma and is still the reference treatment in many
countries. Temozolomide demonstrated efficacy equal to
that of DTIC in two phase III trials [27, 28]. No differ-
ence in overall survival, progression free survival and over-
all response rate was seen between the two arms. One ad-
vantage of temozolomide is the better penetration into the
central nervous system. Several case reports have shown
a regression of CNS metastases under treatment with te-
mozolomide. Treatment with bisphosphonates should be
considered in patients with bone metastases. In aggressive
symptomatic disease, a polychemotherapy containing cis-
platin, vindesine and dacarbacine in first line (response
rate: 40%) [29] or the combination of carboplatin and pac-
litaxel in second line [30] has produced a partial response
in 11% and a disease stabilisation in 51% of the patients.
However, an impact on disease free or overall survival was
not shown in either study.
Biochemotherapy, a combination of IL-2 and/or interferon
alpha with chemotherapeutic agents such as DTIC, temo-
zolomide, fotemustine, cisplatin, carboplatin, vinblastine,
paclitaxel or docetaxel has demonstrated a higher response
rate but this was not translated into a better survival rate
than that with a single agent and has been associated with
an increase in toxicity [31, 32] and is not recommended.
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There are no randomised clinical trials for IL-2 monother-
apy. Some centers still use this therapy in well-selected pa-
tients with low tumor burden, despite the lack of convin-
cing phase III data.
The anti-CTLA4 antibody Ipilimumab has very recently
been shown to prolong overall survival in 1st and 2nd line
therapy of stage IV [33, 34]. Despite the considerable side
effects, this treatment option may be considered as 1st or
2nd line therapy. This treatment should only be applied
in specialised centers that offer translational research pro-
gramme to contribute to a better definition of the patient
subpopulation that profits from this therapy.
A number of new drugs targeting several pathways have
been tested in phase III and failed to show a survival be-
nefit [30]. The selective B-Raf inhibitor vemurafenib
(PLX4032) has been investigated in phase II and III studies
for patients with B-Raf mutations (50% of melanoma pa-
tients) with positive impact on response rate and survival
[35]. In patients with symptomatic melanoma (B-Raf
mutated) metastases (pain, B symptoms, bulky disease)
vermurafenib is considered to be the appropriate first line
therapy.
Other molecules, as anti VEGF antibodies have shown
promising activity in phase II trials [36, 37]. To conclude,
all stage IV melanoma patients need to be referred to ref-
erence centers, discussed in an interdisciplinary melanoma
tumour board at centers with broad experience in the man-
agement of this disease and should be treated preferably in
well-designed clinical trials.
Follow-up
The patient should be instructed in avoidance of sunburn,
extended unprotected solar or artificial ultraviolet exposure
and in lifelong regular self-examination of the skin and
peripheral lymph nodes. The patient must be aware that his
family members have an increased melanoma risk.
The aim of melanoma follow up is to detect a relapse or
an additional skin tumour as early as possible. The risk of
developing a second melanoma is 5–8% within the first 2
years after diagnosis [38]. 35% of patients with lentigo ma-
ligna melanoma develop another malignant tumour of the
skin during the next 5 years [7]. Although the hypothesis
suggesting that regular monitoring reveals early detection
of metastasis may be well founded, no randomised studies
have demonstrated early detection of metastases improves
over all survival [39].
Follow up schedule is based mainly on dated literature and
historical practice [40] (level of evidence IV). Despite nu-
merous attempts to achieve international consensus on fol-
low up guidelines there is no universal valid agreement.
However, loco regional lymph node metastases are the
most common event in patients which are regularly
checked. Therefore, it is worthwhile to focus on cutaneous
relapses and loco regional lymph nodes. Physical exam-
ination remains the mainstay of follow up visits. Besides
that, patients should be trained on self examination because
most relapses have been detected by themselves. This fact
raises the question whether routinely performed clinical ex-
aminations and imaging procedures, based on the relapse
risk over time, generate a real benefit for melanoma pa-
tients [2]. Probably false positive results could be reduced
by increasing the time between visits and would be anyhow
sufficient for psychological support [2].
While the first 5 years after diagnosis are most important,
as 90% of all metastases occur during this period, clinical
examinations and imaging procedures have to be more fre-
quent for the first 5 years. Because melanoma is a tumour
that could have late metastasis, a lifelong surveillance bey-
ond 10 years is generally recommended [41]. Thin melano-
Table 3
Number and localisation of the metastases Treatment modalities
1st choice
2nd choice
3rd choice
In-transit metastases (few) (pTXN2cM0) 1. Surgical removal
2. Radiotherapy
In-transit metastases (multiple, >5) (pTXN2cM0) 1. Perfusion of the extremity1
2. Radiotherapy
3. Chemo-/ targeted / immuno-therapy1
Locoregional lymph nodes (pTxN1a,2a) 1. Consider trial participation
2. Additional Interferon alpha treatment1
Locoregional lymph nodes (pTxN2b,2c,3) 1. Radical lymphadenectomy, in case of incomplete resection: Radiotherapy
2. Consider trial participation
Solitary central nervous system metastases (pTxNxM3) 1. Neurosurgical removal
2. Stereotactic irradiation1
(according to localisation this could also be the 1st choice)
Solitary lung metastases (pTxNxM1) 1. Surgical removal
2. Consider clinical trial participation
3. Chemo-/ targeted / immuno-therapy1
Multiple metastases (pTxNxM1a-1c) 1. Consider clinical trial participation
2. Chemo-/ targeted / immuno-therapy1
Painful bone metastases (pTxNxM1a-1c) 1. Consider clinical trial participation
2. Bone specific therapy
(e.g., bisphosphonates, denosumab)
3. Consider surgical removal if single lesion,
4. Radiotherapy
5. Chemo-/ targeted / immuno-therapy1
1 These therapies should be restricted to controlled studies at specialised centers.
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mas with a Breslow depth less than 1mm have only a small
risk of relapse and thus need no imaging. While sono-
graphy is easy to perform, cheap, not harmful and more
sensitive than clinical examination in revealing lymph node
metastasis it should be routinely done. Table 4 presents
the suggested time schedule of examinations in Switzer-
land. To detect further metastasis in stage III (and in stage
IIC because of similar prognosis) an imaging study of the
whole body, preferably with PET-CT, is recommended
[42]. S-100 protein is a good marker for melanoma relapse,
especially for disease free survival in stage III melanomas
[43, 44]. In stage IV melanomas control intervals have to
be individually adjusted according the therapeutical inten-
tions.
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